•
Sep 30, 2021
89Bio Q3 2021 Earnings Report
89bio reported financial results for the third quarter of 2021 and provided a corporate update.
Key Takeaways
89bio reported a net loss of $28.3 million for the third quarter of 2021. The company's R&D expenses were $23.6 million, and G&A expenses were $4.6 million. As of September 30, 2021, 89bio had cash, cash equivalents, and short-term investments of $157.4 million.
Advanced clinical development program for BIO89-100.
Reported topline data from open-label histology cohort in NASH patients expected in early to mid-January 2022.
Topline data from Phase 2 ENTRIGUE trial in severe hypertriglyceridemia patients expected in the first half of 2022.
Continued enrollment in the ENLIVEN Phase 2b trial of BIO89-100 for the treatment of NASH.